ArriVent BioPharma, Inc. AVBP 深 沪
等待开盘 12-20 09:30:00 美东时间
22.21
+1.040
+4.91%
华盛通- 最 高22.66
- 今 开21.37
- 成交量 21.17万股
- 最 低 21.32
- 昨 收 21.17
- 总市值 9.17亿
- 52周最高 29.71
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 15.47
- 委 比 -86.21%
- 总股本 4128.14万
- 历史最高 36.37
- 量 比 0.45
- 振 幅 6.33%
- 历史最低 14.35
- 每 手 1
- 风险率 3.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
12-17 02:17
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
BTIG Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45
BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $45.
12-10 20:34
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Truist Securities Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $43
Truist Securities analyst Asthika Goonewardene initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $43.
11-26 02:02
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $31
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $33 to $31.
11-12 04:35
ArriVent BioPharma Q3 EPS $(0.83) Misses $(0.81) Estimate
ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.81) by 2.85 percent. This is a 36.07 percent decrease over losses of $(0.61) per share
11-10 21:05
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma announced the appointment of Brent S. Rice as Chief Commercial Officer. With over 25 years of experience in biotech and pharma, Rice will lead commercial efforts for firmonertinib, a potential treatment for EGFR mutant NSCLC, and advance the company's ADC portfolio. Previously, Rice served as CCO at Autolus Therapeutics and held leadership roles at Amgen and Juno Therapeutics, demonstrating success in launching therapies and bu...
09-22 20:05
ArriVent BioPharma Presents Final Proof-Of-Concept Data From Randomized Global Phase 1b FURTHER Trial For First-Line Firmonertinib Monotherapy In Patients With NSCLC Harboring EGFR PACC Mutations At IASCLC 2025
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR)
09-09 20:07
